Diagnosis and treatment of four patients with myeloproliferative neoplasms and a literature review
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 10
- DOI:
- 10.3760/cma.j.issn.1009-9921.2010.10.005
- Key Word:
- 骨髓增殖性疾病;诊断;治疗;Myeloproliferative disorders;Diagnosis;Therapy
Abstract： Objective To analyze the clinical practice of the diagnosis and treatment of four patients with myeloproliferative diseases (MPD) and review the relative literatures. Methods The progress of diagnosing and treating one polycythemia vera patient, two essential thrombocythemia patients and one primary myelofibrosis patient were introduced. Results Interferon alone, interferon combined with hydroxyurea and HLA matched sible allogeneic hematopoietic stem cell transplantation were carried out separately, the satisfying outcomes were shown. Conclusion Detection of genetic mutation of JAK2 V617F has markedly facilitated the approach to clinical diagnosis of MPD. The therapeutic aim for patients with polycythemia vera and essential thrombocythemia is preventing the occurrence thromboembolic events, while for some high-risk primary myelofibrosis patient, allogeneic stem cell transplantation should be considered.
- [1]Hexner EO,Serdikoff C,Jan M,etc.Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.[J].2008,111(12).
- [2]Chloé, James,Valérie, Ugo,Jean-Pierre, Le Couédic,etc.A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.[J].2005,434(7037).
- [3]Skoda RC,Passweg JR,Passamonti F,etc.A gain-of-function mutation of JAK2 in myeloproliferative disorders.[J].2005,352(17).
- [4]Mesa RA,Kroger N.Choosing between stem cell therapy and drugs in myelofibrosis.[J].2008,22(3).
- [5]K, Nishii,R, Nanbu,F, Lorenzo V,etc.Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature.[J].2007,21(6).
- [6]Kutti J,Marchioli R,Gisslinger H,etc.Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.[J].2005,23(10).
- [7]Huntly BJ,Frohling S,D'Andrea A,etc.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.[J].2005,7(4).
- [8]Barosi G,Bacigalupo A.Allogeneic hematopoietic stem cell transplantation for myelofibrosis.[J].2006,13(2).
- [9]Guardiola,P,Anderson,JE,Bandini,G,etc.Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Resear[J].1999,93(9).
- [10]Lodish HF,Beer PA,Levine RL,etc.JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.[J].2007,356(5).
- [11]Steensma DP,McClure RF,Karp JE,etc.JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.[J].2006,20(6).
- [12]B, Dupriez,P, Morel,J L, Demory,etc.Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.[J].1996,88.